Quantum BioPharma is trading 5.78% up now at $3.48 after September 9, 2026 coverage highlighted FDA clearance to begin Phase 2 trials of Lucid-MS, its experimental multiple-sclerosis treatment.
- The therapy is described as a potentially first-in-class approach targeting myelin protection and repair
- The company-specific catalyst supports elevated speculative activity
- No broader market catalyst explains the move; the S&P 500 and Nasdaq were modestly lower